Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say

Executive Summary

Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.

Advertisement

Related Content

Fourth Act For AbbVie's Risankizumab Whets Appetite
Fourth Act For AbbVie's Risankizumab Whets Appetite
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Safety Issues Not Dampening AbbVie Optimism For Humira Successors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel